Cargando…

ADHD symptoms and use of anabolic androgenic steroids among male weightlifters

Use of anabolic androgenic steroids (AAS) is associated with adverse health effects. The factors that predispose to AAS use among athletes are poorly understood, but attention deficit/hyperactivity disorder (ADHD), which is known to occur among athletes more often than in the general population, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kildal, Emilie, Hassel, Bjørnar, Bjørnebekk, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178025/
https://www.ncbi.nlm.nih.gov/pubmed/35676515
http://dx.doi.org/10.1038/s41598-022-12977-w
_version_ 1784722967785111552
author Kildal, Emilie
Hassel, Bjørnar
Bjørnebekk, Astrid
author_facet Kildal, Emilie
Hassel, Bjørnar
Bjørnebekk, Astrid
author_sort Kildal, Emilie
collection PubMed
description Use of anabolic androgenic steroids (AAS) is associated with adverse health effects. The factors that predispose to AAS use among athletes are poorly understood, but attention deficit/hyperactivity disorder (ADHD), which is known to occur among athletes more often than in the general population, is associated with risk behaviors, including substance abuse. We aimed to see if AAS use in male weightlifters was associated with ADHD symptoms, and test the link between ADHD symptoms and cognitive performance. Hundred and forty male weightlifters, 72 AAS users and 68 weightlifting controls (WLC), completed the Achenbach system of empirically based assessment (ASEBA) for ADHD symptoms and underwent cognitive examination. Self-reported ADHD symptom scores were significantly higher among AAS users compared to WLC, and scores in the range indicating clinically important ADHD was significantly more common in the AAS-using group. Age of onset of AAS use correlated inversely with ADHD scale score (r = − 0.35; p = 0.003). ADHD score correlated inversely with cognitive scores for working memory (r = − 0.25, p < 0.001), processing speed (r = − 0.24, p < 0.001), verbal learning and memory (r = − 0.19, p = 0.03), and problem solving (r = − 0.20, p = 0.02). AAS use among weightlifters is associated with ADHD symptoms and corresponding lower cognitive performance. Recognising a relationship between ADHD symptoms and AAS use may guide drug prevention strategies in sports.
format Online
Article
Text
id pubmed-9178025
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91780252022-06-10 ADHD symptoms and use of anabolic androgenic steroids among male weightlifters Kildal, Emilie Hassel, Bjørnar Bjørnebekk, Astrid Sci Rep Article Use of anabolic androgenic steroids (AAS) is associated with adverse health effects. The factors that predispose to AAS use among athletes are poorly understood, but attention deficit/hyperactivity disorder (ADHD), which is known to occur among athletes more often than in the general population, is associated with risk behaviors, including substance abuse. We aimed to see if AAS use in male weightlifters was associated with ADHD symptoms, and test the link between ADHD symptoms and cognitive performance. Hundred and forty male weightlifters, 72 AAS users and 68 weightlifting controls (WLC), completed the Achenbach system of empirically based assessment (ASEBA) for ADHD symptoms and underwent cognitive examination. Self-reported ADHD symptom scores were significantly higher among AAS users compared to WLC, and scores in the range indicating clinically important ADHD was significantly more common in the AAS-using group. Age of onset of AAS use correlated inversely with ADHD scale score (r = − 0.35; p = 0.003). ADHD score correlated inversely with cognitive scores for working memory (r = − 0.25, p < 0.001), processing speed (r = − 0.24, p < 0.001), verbal learning and memory (r = − 0.19, p = 0.03), and problem solving (r = − 0.20, p = 0.02). AAS use among weightlifters is associated with ADHD symptoms and corresponding lower cognitive performance. Recognising a relationship between ADHD symptoms and AAS use may guide drug prevention strategies in sports. Nature Publishing Group UK 2022-06-08 /pmc/articles/PMC9178025/ /pubmed/35676515 http://dx.doi.org/10.1038/s41598-022-12977-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kildal, Emilie
Hassel, Bjørnar
Bjørnebekk, Astrid
ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title_full ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title_fullStr ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title_full_unstemmed ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title_short ADHD symptoms and use of anabolic androgenic steroids among male weightlifters
title_sort adhd symptoms and use of anabolic androgenic steroids among male weightlifters
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178025/
https://www.ncbi.nlm.nih.gov/pubmed/35676515
http://dx.doi.org/10.1038/s41598-022-12977-w
work_keys_str_mv AT kildalemilie adhdsymptomsanduseofanabolicandrogenicsteroidsamongmaleweightlifters
AT hasselbjørnar adhdsymptomsanduseofanabolicandrogenicsteroidsamongmaleweightlifters
AT bjørnebekkastrid adhdsymptomsanduseofanabolicandrogenicsteroidsamongmaleweightlifters